ClinicalTrials.gg
Not yet recruitingNCT07880886Updated Oct 19, 2026

Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever

A Phase 3 interventional study of RPH-104 in Familial Mediterranean Fever and FMF, sponsored by R-Pharm. Not yet recruiting at 3 sites in Russia. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by R-Pharm · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Study summary

The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).

Read the detailed description

This is an open-label, non-randomized clinical study in pediatric and adolescent participants.

The study consists of three periods:

  • the screening period (up to 12 weeks) which includes a period for evaluating eligibility criteria and monitoring "marker" attacks
  • treatment period, up to 56 weeks including:

    • 16-week main treatment period
    • 40-week long-term treatment period
  • 8-week safety follow-up

The total maximum duration of participation of one participant in the study is up to 76 weeks, i.e. approximately 1 year and 6 months.

The study enrolls participants in two sequential cohorts. Cohort 1 includes 6 adolescents aged 12-14 years in the Kingdom of Saudi Arabia (KSA) and 12-17 years in other countries. An interim safety and pharmacokinetic (PK) analysis will be performed. If enrollment of participants aged 5-17 years is considered feasible, Cohort 2 enrolls participants aged 5-14 years in the KSA and 5-17 years in other countries, until at least 18 participants receive the investigational treatment.

02

Conditions studied

  • Familial Mediterranean Fever
  • FMF

Keywords

  • RPH-104
  • colchicine inefficacy
  • colchicine intolerance
  • colchicine resistance
  • FMF
  • interleukin-1 inhibitor
  • Pediatric and adolescent patients
03

In context

Familial Mediterranean Fever

61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.

This study's planned enrollment of 18 is below the median of 40 across 27 interventional studies indexed under Familial Mediterranean Fever.

Browse Familial Mediterranean Fever studies →

Lead sponsor

R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of Familial Mediterranean Fever (FMF) based on new diagnostic criteria of the Eurofever/PRINTO expert group (2019)
  2. Male and female participants aged ≥ 5 and \< 18 years at the time of signing Form (ICF) and Visit 1, respectively:

    2.1. In Kingdom of Saudi Arabia, the upper age limit is 14 years (i.e. the participants should be between ≥ 5 and ≤ 14 years old)

    2.2. In other countries, the upper age limit is 18 years (i.e. the participants should be between ≥ 5 and \< 18 years old)

  3. Availability of a voluntarily signed and dated ICF for participation in this study: the informed consent of the parent or legal representative and the consent of the child
  4. Availability of one of the documented data listed below (at the time of the start of screening) (records of medical examinations/consultations including those done by the investigator, hospital discharges) confirming:

    4.1. colchicine resistance at the maximum tolerated therapeutic dose (depending on age and weight) confirmed by the persistence of at least one attack of the disease per month on average, despite the indicated therapy for at least the last 3 months before the start of screening. Colchicine administration will be continued at stable dose if it is not associated with unacceptable adverse drug reactions

    4.2. intolerance to therapeutic or subtherapeutic doses of colchicine (presence of unacceptable adverse drug reactions). The dose of colchicine should be stable for at least 5 days before the participant is enrolled (before screening)

  5. Ability of the participant and the parent (legal representative) and willingness, in the reasoned opinion of the investigator, to visit the study site during all scheduled visits, to perform the study-related procedures and comply with the Protocol requirements including consent to undergo subcutaneous injections by qualified personnel of the site
  6. One active attack with a duration of no more than 2 days (48 hours) at the time of Visit 1 defined as the development of both clinical and serological signs of an attack including:

    1. Physician's Global Assessment (PGA) score ≥ 2 suggesting "mild", "moderate", or "severe" disease activity (i.e. clinical signs)
    2. C-reactive protein (CRP) level > 10 mg/L (i.e. serological signs)
  7. The Russian Federation, the Hashemite Kingdom of Jordan and the Republic of Turkey: Consent of female adolescents, after menarche, to use highly effective throughout the study, starting from the screening (signing ICF) and for at least 8 weeks after completion (termination) of the study therapy; as well as the presence of a negative pregnancy test (serum test for chorionic human gonadotropin (HCG)) OR Consent of sexually active male adolescents to use highly effective contraceptives throughout the study, starting from the screening (signing ICF) and for at least 8 weeks after completion (termination) of the study therapy

Exclusion criteria

Exclusion Criteria:

  1. to GFC and/or its components/
  2. Administration of live (attenuated) vaccine less than 3 months prior to Visit 1 (treatment period initiation) and/or necessity to use such vaccine within 3 months after GFC discontinuation
  3. Conditions or signs which, according to the investigator, suggest impaired (reduced) immune response and/or significantly increase the risk of immunomodulating therapy including (but not limited to):

    3.1. any acute or chronic active infection at the time of screening, an infection requiring antimicrobial therapy within 4 weeks prior to screening, or a history of serious, opportunistic, or frequently recurring infection within 6 months prior to screening

    3.2. presence of infection caused by the (HIV), virus or virus

  4. History of active or latent tuberculosis (TB) or existing risk factors or signs suggestive of active or latent M. tuberculosis including (not limited to) the following:

    4.1. living or working in specific conditions that increase the risk of contact with participants with TB, such as residential care, places of deprivation of liberty, communities of persons without a special place of residence, etc. during the last year before the start of the treatment period

    4.2. close contact, i.e. living at the same premises (at home or in another enclosed environment) for a prolonged period of time (several days or weeks, rather than minutes or hours) with a person with active pulmonary TB during the last year before the start of the treatment period

    4.3. results of examinations indicating active or latent infection with M. tuberculosis: positive QuantiFERON-TB / T-SPOT.TB test at screening; chest Xray/CT findings confirming pulmonary TB during screening

  5. Any other relevant concomitant diseases or conditions that, in the Investigator's judgment, may affect the participant's participation or well-being in the study and/or interfere with the assessment of study results
  6. History of organ transplantation or necessity in transplantation at the screening onset
  7. Surgical intervention within 8 weeks prior to the screening or planned for the period of participation in the study, which, in the investigator's opinion, agreed with the Sponsor, will generate an unacceptable risk for the participant
  8. Any existing malignant neoplasm during the screening period or within 5 years prior to screening, including blood and lymphatic neoplasm, except non- basal cell and squamous cell skin cancer after complete resection or carcinoma in situ of any type after complete resection
  9. Pregnancy or breast-feeding
  10. History of alcohol or psychoactive substances abuse, according to the investigator's evaluation
  11. Previous administration of:

    • rilonacept - less than 6 weeks prior to Day 0 of the study
    • canakinumab - less than 12 weeks prior to Day 0 of the study
    • anakinra - less than 72 hours prior to Day 0 of the study
    • rituximab - less than 24 weeks before day 0
    • tumor necrosis factor (TNF) inhibitors, IL-6 inhibitors and other biological medications with an mechanism of action - less than 6 weeks or 5 half-lives (whichever is longer) before study day 0
    • immunosuppressants (azathioprine, leflunomide, dapsone, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, mercaptopurine, methotrexate, etc.) - less than 4 weeks or 5 elimination half-lives (whichever is longer) before study day 0. In case of leflunomide administration complete elimination course using cholestyramine should be documented
    • intravenous (IV) immunoglobulin (Ig) - less than 8 weeks before day 0;
    • intravenous administration of - less than 1 week (from the end of therapy) to study day 0
    • intramuscular, intra-articular or periarticular administration of glucocorticoids - less than 4 weeks before day 0
    • systemic oral glucocorticoid therapy at doses > 0.2 mg/kg/day of prednisolone equivalent on day 0
    • changes in the dose/treatment regimen of oral glucocorticoids during the 4 weeks prior to the screening
  12. Any of the deviations in the laboratory tests below:

    • \< 1.5×10\^9/L (\< 1500/mm\^3)
    • white blood cell (WBC) count \< 3×10\^9/L (\< 3000/mm\^3)
    • count \< 100×10\^9/L (\< 100 000/mm\^3 or \< 100 000×10\^6/L)
    • and/or AST ≥ 2.0 × (ULN); if ALT and/or AST is ≥ 2 × ULN but \< 3 × ULN at the screening, retest is allowed
    • > 1.5 x ULN (except for confirmed Gilbert's disease)
  13. Concomitant participation in other clinical studies at the screening onset or administration of any unauthorized () medications less than 4 weeks or 5 half-life periods (whichever is longer) before Visit 1 (treatment initiation)
  14. Prior participation in this clinical study in case of at least one GFC dose
  15. Severe renal failure: (GFR) calculated by Schwartz formula is \< 45 mL/min/1.73 m\^2
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    RPH-104

    RPH-104 subcutaneously at 2.2 mg/kg on Day 0, followed by 1.1 mg/kg on Days 7 and 14 and then every 2 weeks (q2w). The dose may be increased to 2.2 mg/kg q2w (maximum 160 mg) in non-responders or participants with recurrent familial Mediterranean fever (FMF) attacks.

    Biological: RPH-104

Interventions

  • BiologicalRPH-104

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial.

    Also known as: Arcerix, goflikicept

06

What researchers measure

Primary outcomes

  1. Maximum serum concentration of goflikicept (Cmax (W16))

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)

  2. Area under serum concentration-time curve for goflikicept (AUC(0-W16))

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)

Secondary outcomes

  1. Changes in trough serum goflikicept concentration

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)

  2. Trough serum steady-state concentration of goflikicept (Cmin,ss)

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)

  3. Area under curve for the dosing interval (t) at steady state (ss) after repeated injections (AUC0-t,ss)

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)

  4. Time to steady state

    Time frame: Visit 1 (Baseline) to Visit 10 (Week 16), and Visit 16 (Week 56)

  5. Percentage of participants with a complete response to treatment

    Complete response is defined as resolution of a "marker" familial Mediterranean fever (FMF) attack by day 7 and the absence of recurrent (new) attacks during the treatment period.

    Time frame: Up to Visit 16 (Week 56)

  6. Change from baseline in PGA (Physician Global Assessment) score

    The Physician's Global Assessment (PGA) is an investigator-rated 5-point scale used to evaluate overall disease activity. Scores range from 0 to 4, where: 0 = none; 1 = minimum; 2 = mild; 3 = moderate; 4 = severe signs and symptoms. Higher scores indicate greater disease severity.

    Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)

  7. Change from baseline in C-reactive protein (CRP) level

    Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)

  8. Change from baseline in serum amyloid A (SAA) level

    Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)

  9. Percentage of participants with serological remission (C-reactive protein < 10 mg/L)

    Serological remission is defined as a C-reactive protein (CRP) level of less than 10 mg/L.

    Time frame: Up to Visit 16 (Week 56)

  10. Time to a recurrent (new) FMF attack in participants with a resolved "marker" attack

    Recurrent (new) Familial Mediterranean Fever (FMF) attack is defined as the presence of both clinical and serological signs of an attack after resolution of the "marker" attack.

    Time frame: Visit 2 (Week 1) to Visit 16 (Week 56)

  11. Percentage of participants who were administered an increased dose of goflikicept 2.2 mg/kg once every 2 weeks

    Time frame: Up to Visit 16 (Week 56)

  12. Frequency, Severity, Nature, and Outcomes of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Adverse event (AE) severity is assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Up to Visit 16 (Week 56)

  13. Percentage of participants with anti-drug antibodies (ADA)

    Time frame: Up to Visit 16 (Week 56)

  14. Number of participants with clinically significant laboratory abnormalities

    Laboratory parameters include: * Hematology * Blood Biochemistry * Measurement of the concentration of immunoglobulin type G (IgG) * Urinalysis

    Time frame: Up to Visit 16 (Week 56)

  15. Number of participants with clinically significant vital sign abnormalities

    Measurement of vital signs includes: * body temperature (in degrees Celsius) * blood pressure (BP) (one arm, mm Hg) * heart rate (HR) (bpm) * respiratory rate (RR) (per min)

    Time frame: Up to Visit 16 (Week 56)

  16. Percentage of participants with Physician Global Assessment (PGA) score < 2 at each visit

    The Physician's Global Assessment (PGA) is an investigator-rated 5-point scale used to evaluate overall disease activity. Scores range from 0 to 4, where: 0 = none; 1 = minimum; 2 = mild; 3 = moderate; 4 = severe signs and symptoms. Higher scores indicate greater disease severity.

    Time frame: Up to Visit 16 (Week 56)

  17. Сhange from baseline in the overall disease activity assessed by the participant/parent (Visual analogue scale)

    Assessment of the disease activity by the subject/legal representative is performed using a visual analog scale (VAS) in mm (0-100), where 0 mm = very good, 100 mm = very bad.

    Time frame: at Visit 1 (Baseline) and Visit 16 (Week 56)

  18. Percentage of participants with a partial response

    Partial response is defined as resolution of a "marker" familial Mediterranean fever (FMF) attack by day 7 and the presence of recurrent (new) attacks during the treatment period.

    Time frame: Up to Visit 16 (Week 56)

  19. Percentage of participants with normal serum amyloid A levels

    Percentage of participants whose serum amyloid A (SAA) levels return to normal (\<10 mg/L) at each study visit.

    Time frame: Up to Visit 16 (Week 56)

  20. Percentage of participants receiving additional symptomatic therapy

    Includes additional symptomatic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol (acetaminophen), or glucocorticoids.

    Time frame: Up to Visit 16 (Week 56)

  21. Percentage of participants who prematurely discontinued therapy due to Adverse Events (AEs)

    Time frame: Up to Visit 16 (Week 56)

  22. Percentage of participants with neutralizing antibodies (NAb)

    Time frame: Up to Visit 16 (Week 56)

  23. Number of participants with clinically significant electrocardiogram (ECG) abnormalities

    Time frame: Up to Visit 16 (Week 56)

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2029, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 19, 2026
StartEst.
Dec 2026
Primary completionEst.
May 2029
CompletionEst.
Apr 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07880886
Lead sponsor
R-Pharm
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
Apr 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Yulia Karpova
Contact
jn.karpova@rpharm.ru
+7 (495) 956-79-37 ext. 1197
Darya Bukhanova
Contact
bukhanova@rpharm.ru
+7 (495) 956-79-37
Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goflikicept

Start the discussion